Cardiovascular mortality in patients with subclinical Cushing.

[1]  I. Chiodini,et al.  Predictability of hypoadrenalism occurrence and duration after adrenalectomy for ACTH-independent hypercortisolism , 2018, Journal of Endocrinological Investigation.

[2]  M. Debono,et al.  Resetting the Abnormal Circadian Cortisol Rhythm in Adrenal Incidentaloma Patients With Mild Autonomous Cortisol Secretion , 2017, The Journal of clinical endocrinology and metabolism.

[3]  M. Copetti,et al.  Cardiovascular events in patients with mild autonomous cortisol secretion: analysis with artificial neural networks. , 2017, European journal of endocrinology.

[4]  M. Bufi,et al.  Clinical Benefits of Unilateral Adrenalectomy in Patients with Subclinical Hypercortisolism Due to Adrenal Incidentaloma: Results from a Single Center , 2017, High Blood Pressure & Cardiovascular Prevention.

[5]  M. D. De Martino,et al.  Six controversial issues on subclinical Cushing’s syndrome , 2017, Endocrine.

[6]  I. Chiodini,et al.  Follow-up of patients with adrenal incidentaloma, in accordance with the European society of endocrinology guidelines: Could we be safe? , 2017, Journal of Endocrinological Investigation.

[7]  Fares Alahdab,et al.  THERAPY OF ENDOCRINE DISEASE: Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing's syndrome: a systematic review and meta-analysis. , 2016, European journal of endocrinology.

[8]  A. Turchin,et al.  Nonfunctional Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes , 2016, Annals of Internal Medicine.

[9]  A. Tabarin,et al.  Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. , 2016, European journal of endocrinology.

[10]  Mustafa Gök,et al.  Carotid Intima-Media Thickness as the Cardiometabolic Risk Indicator in Patients with Nonfunctional Adrenal Mass and Metabolic Syndrome Screening , 2016, Medical science monitor : international medical journal of experimental and clinical research.

[11]  M. Bradburn,et al.  Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. , 2014, The Journal of clinical endocrinology and metabolism.

[12]  R. Golfieri,et al.  Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. , 2014, The lancet. Diabetes & endocrinology.

[13]  E. Ghigo,et al.  Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. , 2014, The Journal of clinical endocrinology and metabolism.

[14]  M. Debono,et al.  Visceral fat accumulation and postdexamethasone serum cortisol levels in patients with adrenal incidentaloma. , 2013, The Journal of clinical endocrinology and metabolism.

[15]  R. Eastell,et al.  Mifepristone Reduces Insulin Resistance in Patient Volunteers with Adrenal Incidentalomas That Secrete Low Levels of Cortisol: A Pilot Study , 2013, PloS one.

[16]  C. Letizia,et al.  Epicardial fat thickness and left ventricular mass in subjects with adrenal incidentaloma , 2013, Endocrine.

[17]  C. Mosconi,et al.  Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. , 2012, European journal of endocrinology.

[18]  F. Guaraldi,et al.  Glucose metabolism in patients with subclinical Cushing’s syndrome , 2012, Endocrine.

[19]  K. Sworczak,et al.  The estimation of selected endogenous anticoagulation system parameters in patients with subclinical Cushing's syndrome. , 2011, European journal of endocrinology.

[20]  E. Papini,et al.  AME position statement on adrenal incidentaloma. , 2011, European journal of endocrinology.

[21]  Ž. Crnčević-Orlić,et al.  Health-related quality of life and fatigue in patients with adrenal incidentaloma , 2011, Endocrine.

[22]  I. Chiodini.  Diagnosis and Treatment of Subclinical Hypercortisolism , 2011 .

[23]  I. Chiodini,et al.  Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma. , 2010, European journal of endocrinology.

[24]  I. Chiodini,et al.  Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects , 2010, Clinical endocrinology.

[25]  I. Chiodini,et al.  Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. , 2009, The Journal of clinical endocrinology and metabolism.

[26]  K. Karlinger,et al.  Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study. , 2009, European journal of endocrinology.

[27]  A. Comlekçi,et al.  Carotid intima media thickness is increased and associated with morning cortisol in subjects with non-functioning adrenal incidentaloma , 2009, Endocrine.

[28]  B. Biondi,et al.  Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. , 2002, The Journal of clinical endocrinology and metabolism.

[29]  P. Paccotti,et al.  Adrenal incidentaloma: a new cause of the metabolic syndrome? , 2002, The Journal of clinical endocrinology and metabolism.

[30]  M. Reincke.  Subclinical Cushing's syndrome. , 2000, Endocrinology and metabolism clinics of North America.

[31]  G. Krestin,et al.  Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome. , 1992, The Journal of clinical endocrinology and metabolism.